Skip to the main content.

Cell and Gene Therapy Series. Part 3 - Clusters, Megadeals, "Cellicon Valley" and the "Golden Triangle

Dr. Dave Seaward : 28 February 2022

Cell and Gene Therapy Series. Part 3 - Clusters, Megadeals,

In this third instalment to our cell and gene blog series, author Dave Seaward explains where most ATMP technology is being delivered as well as providing insight into why.

Click here to gain an understanding of why investors believe significant returns will be made from these technologies.
From Disruption to Reinvention: The Story of API-in-Capsule Technology and Its Future

From Disruption to Reinvention: The Story of API-in-Capsule Technology and Its Future

Tom French: 28 July 2025

From Disruption to Reinvention: The Story of API-in-Capsule Technology and Its Future This article traces the evolution of API-in-capsule (AIC)...

Read More
What does Annex 1 mean for the cell & gene industry? Insights from 3P innovation.

What does Annex 1 mean for the cell & gene industry? Insights from 3P innovation.

Charles Pilato: 17 July 2025

The revision of EU GMP Annex 1 has redefined expectations for sterile manufacturing across the life sciences sector and nowhere is this felt more...

Read More
How do we reduce your Environmental Cost of Ownership (ECO)?

How do we reduce your Environmental Cost of Ownership (ECO)?

David Johnson: 16 July 2025

Today’s pharmaceutical landscape positions 'sustainability' as an operational imperative. Manufacturers face increasing regulatory, societal, and...

Read More